Clinical meaning
Opioid analgesics exert their effects through mu, kappa, and delta opioid receptors, which are G-protein coupled receptors that inhibit adenylyl cyclase, reduce calcium influx, and increase potassium conductance, resulting in neuronal hyperpolarization and decreased neurotransmitter release. The mu receptor is the primary target for analgesia but also mediates respiratory depression, euphoria, and physical dependence — tolerance develops through receptor desensitization and downregulation with chronic exposure. Pharmacogenomic variations in CYP2D6 metabolism significantly affect codeine and tramadol efficacy: ultra-rapid metabolizers convert codeine to morphine at dangerous rates, while poor metabolizers receive no analgesic benefit. The clinician prescribing opioids must integrate equianalgesic dosing calculations, opioid rotation strategies, and multimodal analgesia principles to optimize pain management while minimizing adverse effects and addiction risk.
Diagnosis & workup
Diagnostics & workup: - Pharmacogenomic testing for CYP2D6 and CYP3A4 status when indicated - Urine drug screening with confirmation testing - Prescription Drug Monitoring Program (PDMP) query before prescribing - Hepatic function panel for opioid metabolism assessment - Renal function (GFR) for dose adjustment calculations - QTc interval monitoring for methadone therapy